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Abstract. 10 
Rho is a hexameric molecular motor that functions as a conserved transcription 11 
terminator in majority of the bacterial species, which is a potential drug target. Psu is a 12 
bacteriophage P4 capsid protein that inhibits E.coli Rho by obstructing its ATPase and 13 
translocase activities. Here, we explored the anti-Rho activity of Psu for the Rho proteins 14 
from different pathogens. Sequence alignment and homology modelling of Rho proteins from 15 
pathogenic bacteria revealed the conserved nature of the Psu-interacting regions in all these 16 
proteins. We chose Rho proteins from various pathogens like, Mycobacterium smegmatis, 17 
Mycobacterium bovis, Mycobacterium tuberculosis, Xanthomonas campestris, Xanthomonas 18 
oryzae, Corynebacterium glutamicum, Vibrio cholerae, Salmonella enterica and 19 
Pseudomonas syringae. The purified recombinant Rho proteins of these organisms showed 20 
variable rates of ATP hydrolysis on the poly (rC) as substrate and were capable of releasing 21 
RNA from the E. coli transcription elongation complexes. Psu was capable of inhibiting these 22 
two functions of all these Rho proteins. In vivo pull down assays revealed direct binding of 23 
Psu with many of these Rho proteins.  In vivo expression of psu induced killing of M. 24 
smegmatis, M. bovis, X.campestris, and S.enterica, indicating Psu-induced inhibition of Rho 25 
proteins of these strains under physiological conditions. We propose that the “universal” 26 
inhibitory function of the Psu protein against the Rho proteins from both the gram-negative 27 
and gram-positive bacteria could be useful for designing peptides having anti-microbial 28 
functions, and these peptides could be a part of synergistic antibiotic treatment of the 29 
pathogens through compromising the Rho functions. 30 
Importance 31 
Bacteriophage-derived protein factors modulating different bacterial processes could 32 
be converted into unique antimicrobial agents. Bacteriophage P4 capsid protein Psu is an 33 
inhibitor of E. coli transcription terminator, Rho. Here we show that apart from antagonising 34 
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E. coli Rho, Psu is able to inhibit Rho proteins from various phylogenetically unrelated gram-35 
negative and gram-positive pathogens. Psu upon binding to the Rho, exerted the inhibition by 36 
affecting the ATPase and RNA release functions of these Rho proteins. The expression of 37 
Psu in vivo kills various pathogens like, Mycobacterium and Xanthomonas. Hence, Psu could 38 
be useful to identify peptide sequences having anti-Rho activities and might be a part of 39 
synergistic antibiotic treatment against the pathogens.  40 
 41 
Key words: Rho, Psu, transcription termination, RNA polymerase, pathogen 42 
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Introduction 44 
The Rho-dependent transcription termination in bacteria is an important step in 45 
regulation of gene expression (1-5). The homo-hexameric transcription terminator, Rho is a 46 
RNA-dependent helicase motor that functions as a transcription terminator. Upon its 47 
association with the rut site on nascent RNA emerging from the elongation complex (EC) (6, 48 
7), it becomes ATPase competent and translocates along the RNA towards the EC, and 49 
eventually dislodges the latter (8). Recent studies have revealed that Rho-dependent 50 
termination is involved and instrumental in regulating many physiological processes (9). This 51 
multifaceted functional outcome of the Rho-dependent termination process makes Rho an 52 
ideal target of different bactericidal agents. With the emergence of multi-drug resistant 53 
(MDR) and extensively drug-resistant (XDR) strains, it has become necessary to look for 54 
alternative avenues and additional drug targets. It is likely that due to its involvement in many 55 
physiological pathways, Rho-inhibition could be part of a synergistic antibacterial treatment 56 
strategy. 57 
The Psu (polarity suppression) is an unconventional capsid organizing protein of the 58 
bacteriophage P4 that moonlights as a specific inhibitor of Rho (10). It binds and antagonizes 59 
Rho in trans by creating mechanical hindrance to  Rho translocation (11) via a physical 60 
blockade of the RNA exit point of the Rho central channel upon formation of a V-shaped 61 
cap-like knotted homodimer structure (12, 13).   Psu is an α-helical protein having a solvent-62 
exposed flexible C-terminal domain (helices 6 and 7; Ref. 12) that is responsible for its 63 
association with Rho, and a N-terminal domain that sustains the stability of the protein (14).  64 
Overexpression of Psu in E. coli induces lethality due to robust antitermination at the Rho-65 
dependent terminators throughout the genome. Rho contains an unstructured loop-forming 66 
stretch of residues in its C-terminal domain that binds with Psu (figure 1B), which is assisted 67 
by another helical region that surrounds the Rho central channel (13). 68 
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We hypothesized that the bacteriophage derived Psu might be useful for functioning 69 
as a platform to design new antagonist(s) of the Rho protein, especially those made from the 70 
C-terminal helices 6 and 7.  So far, the antagonism of Psu was demonstrated for the Rho 71 
protein from the model organism E. coli.  In order to establish it as a platform for drug-72 
design, it is imperative to prove universal antagonism of Psu against various Rho proteins 73 
both from the gram-positive and gram-negative bacteria.  In this report, we have chosen and 74 
characterized the biochemical activities of the Rho proteins of selected bacterial pathogens 75 
like, Mycobacterium tuberculosis, Salmonella enterica, Vibrio cholerae, Xanthomonas 76 
oryzae, Xanthomonas campestris, Pseudomonas syringae and Corynebacterium glutamicum. 77 
In vitro biochemical assays showed that Psu is capable of inhibiting the ATPase functions of 78 
these Rho proteins. These Rho proteins were unable to terminate at a Rho-dependent 79 
terminator in the presence of Psu.  Psu also inhibited RNA release by these Rho from a 80 
stalled EC and showed direct interaction with these proteins. In vivo expression of psu in the 81 
M. smegmatis, M. bovis and X. campestris induced severe growth defects to the hosts, and it 82 
inhibited the S. enterica Rho functioning in E. coli. These results strongly indicated that Psu 83 
is capable of functioning as a bona fide antagonist of Rho proteins from a wide spectrum of 84 
bacterial species. We further speculate that derivatives of Psu could be a part of synergistic 85 
antibiotic treatment by offering bacterial pathogens with compromised Rho functions. 86 
 87 
Results 88 
Selection of different pathogenic bacteria.  89 
To establish the universal antagonism of the bacteriophage P4 coat protein, Psu, 90 
against the Rho proteins from a diverse set of bacteria, we have chosen the bacterial species, 91 
Salmonella, Vibrio, Xanthomonas, Pseudomonas that are the Gram-negatives, and 92 
Mycobacteria and Corynebacteria are from the Gram-positive category.  They are pathogens 93 
for a wide variety of organisms; Xanthomonaus oryzae (Rice), Xanthomonas campestris 94 
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(Cabbage, Mustard) and Pseudomonas syringae (wide variety of hosts) are the phyto-95 
pathogens, while Salmonella typhi, Vibrio cholerae, Mycobacterium tuberculosis, and 96 
Cornebacterium diptherae are human pathogens.  For each of the human pathogens, we have 97 
carried out experiments also with their non-pathogenic porotypes such as M. smegmatis and 98 
M. bovis (BCG) and C. glutamicum. The phylogenetic tree, constructed based on the 16S 99 
rRNA sequence of these bacterial species is shown in the figure 1A, and it confirms the 100 
diversity of these pathogens.  Majority of these organisms are slow-growing species having 101 
contrasting features compared to E. coli, and it is expected that the Rho proteins in each of 102 
these species function under varied physiological conditions. Therefore, it is important to 103 
establish the inhibitory power of Psu against each of them individually.  104 
Comparison of Rho proteins from different pathogens.  105 
Earlier studies from our laboratory, revealed the existence of a conserved 106 
disorganized loop region connecting the N-terminal to the C-terminal domains of the  E. coli 107 
Rho, to be the main interacting site of Psu (figure 1B-D) (13). A multiple sequence alignment 108 
analysis revealed that this particular loop region is well conserved in different Rho proteins 109 
(figure 1B). To establish the structural conservation of this loop region, we built homology 110 
models of Rho proteins from different bacterial pathogens that we have chosen for our studies 111 
using the published structure of E.coli Rho as the template (figures 1C and D; PDB 3ICE) 112 
(15). The modelling showed that the Psu-binding loops on different Rho proteins are surface 113 
exposed and accessible to the solvent.  However, the size and the finer structural details of the 114 
loops varied in the different Rho proteins.  The structural conservation of the Psu-binding 115 
regions of all these Rho proteins is suggestive of the Psu-Rho interaction in these species. 116 
Characterization of the Rho proteins from different pathogens. 117 
Rho proteins of the bacterial species that we have chosen for our study were not 118 
characterized except those from the S. enterica (16) and M. tuberculosis (17). Therefore, 119 
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characterization of all these Rho proteins are important before attempting to establish the 120 
inhibitory property of Psu against them.  We cloned and purified the recombinant versions of 121 
all these Rho proteins from E.coli (figure 2A). We were unable to express the M. smegmatis 122 
Rho in different varieties of the BL21 (DE3) cells under different conditions, thus we 123 
proceeded in vitro experiments only with the M. tuberculosis Rho. 124 
We used poly (rC), the best co-factor that induces the ATPase function of the E.coli 125 
Rho, to measure the rates of ATPase activities of all these different Rho proteins (figures 2 B-126 
D). The rates are tabulated in figure 2D.  The rate of ATPase activity of the Salmonella Rho 127 
was observed to be comparable to that of the E. coli, whereas that exhibited by the Rho 128 
proteins of M. tb, C. glutamicum and P. syringae were the slowest in the presence of poly 129 
(rC) (> 10-fold slower; note the scale differences of the X-axes in the different plots). The 130 
same rates obtained for the Rho proteins of V.cholerae, X. campestris and X.oryzae were 2.5-131 
4-fold slower than their E.coli counterpart.  132 
V. cholerae, a Gram-negative bacterium belongs to a different family from that of the 133 
E. coli (see figure 1A). Rho from this species has several residual differences in the primary 134 
RNA binding site (PBS; figure S1) compared to that of E. coli. The Xanthomonas species are 135 
Gram-negative plant pathogens having high GC content in their genome. The X. oryzae and 136 
X. campestris Rho sequences are almost similar to each other with only three amino acids 137 
differences in the PBS, while having considerable differences with their E. coli counterpart. 138 
Both the Xanthomonas species have a 7 amino acids insertion at the beginning of the N-139 
terminal domain (NTD) and several residue changes in the PBS, ATP-binding sites and 140 
secondary RNA binding sites (SBS) when compared to the E. coli Rho. Pseudomonas 141 
syringae is also a Gram-negative plant pathogen and its Rho protein has residue differences 142 
from the E.coli Rho in both the PBS and SBS regions.  The Mycobacteria and 143 
Corynebacteria are gram-positive organisms having highly GC-rich genome and their Rho 144 
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proteins have an extended NTD insertion, a smaller insertion (six amino acids in M. 145 
tuberculosis and eleven amino acids in C. glutamicum) as well as amino acid sequence 146 
differences from the E.coli Rho in the PBS. Some of them also have alterations in the 147 
residues in both the ATP-binding sites and the SBS (see figure S1).  148 
Even though the homology model building (figure 1C and D) suggests an overall 149 
similarity in the 3D structure of all these Rho proteins, these diversities at the amino acid 150 
sequence level might have affected the sequence specific interactions between the poly(rC) 151 
and the Rho-PBS.  It is possible that the poly(rC) is not the optimum substrate for many of 152 
these Rho proteins. Weak interactions at the PBS is likely to be the major reason for the 153 
slower ATPase activities. In addition to the sequence variations, the Rho proteins from the 154 
gram-positive bacteria have an extended NTD insertion, which could have caused some 155 
effects.  Moreover, all the organisms, other than Salmonella and Vibrio, have distinctively 156 
longer generation times or slower growth rates, compared to that of E. coli. This specific trait 157 
is also consistent with the slow rate of ATPase activity of their respective Rho proteins. 158 
In spite of this wide range of ATPase activities of all these Rho proteins, we have 159 
used this basic property of Rho because it is a hallmark for any ATPases to study the effect of 160 
Psu using either poly(rC) (both long and oligomers) or natural RNA with E.coli Rho-161 
dependent terminator sequences as the co-factor.   162 
Inhibition of ATPase activity by the Psu protein. 163 
Psu inhibits the ATPase activity of the E. coli Rho quite efficiently (11).  We 164 
performed the ATPase activity assays of different Rho proteins both in the presence and 165 
absence of the Psu in a similar way as described before. In addition to the WT Psu, we have 166 
also used a non-functional Psu mutant, CTD (having a 10 amino acids deletions in its C-167 
terminal; 11) as a negative control. Using poly(rC) as an inducer, we observed that the 168 
ATPase activities of the Rho proteins from the M.tb and the C.glutamicum were efficiently 169 
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inhibited by Psu (figure 3A), whereas the inhibition was moderate for the Rho proteins from 170 
both the Xanthomonas species.  In the presence of poly(rC), we did not observe significant 171 
inhibition of the ATPase activities of the Rho proteins from the Salmonella, Pseudomonas 172 
and Vibrio species.  We repeated the experiments with a shorter poly(rC) oligo, rC25 , to slow 173 
down the rate of ATPase activity (18).  Now Psu was able to inhibit the ATPase activity of 174 
the Rho from the Salmonella sp.  However, the ATPase function of the Rho proteins from the 175 
Vibrio and Pseudomonas still was mildly affected by Psu.  It should be noted that in case of 176 
the E. coli Rho, we used a natural RNA having λtR1 terminator sequence because its ATPase 177 
activity on the poly(rC) is too fast and could not be inhibited by the Psu (11). The mutant Psu 178 
failed to illicit inhibition to any of the Rho proteins used in this study.   These results indicate 179 
that in general, Psu-mediated inhibition occurred more readily when the rates of ATPase 180 
activity were slow.  The ineffectiveness of Psu on the ATPase functions of the Pseudomonas 181 
Rho protein suggests that it may not be an efficient inhibitor for this protein. 182 
Inhibition of in vitro transcription termination by Psu protein. 183 
Psu is capable of inhibiting E.coli Rho-dependent termination in an in vitro purified 184 
system (11).  Next, we assayed the Psu mediated inhibition of the transcription termination 185 
functions of the different Rho proteins chosen for this study using the E.coli transcription 186 
system.  We have used a linear DNA template carrying the λtR1 terminator sequence cloned 187 
downstream of a strong T7A1 promoter (figure 3B).  On this template, a 22-mer EC (EC23) 188 
was made first and then was chased with 20 μM NTPs through the terminator region in the 189 
presence of only Rho or Rho with WT Psu (figure 3B). We used lower concentrations of 190 
NTPs, to check the activity of Psu. Under this  stringent condition the E.coli Rho is very 191 
efficient for termination, but  under the same condition, among all the Rho proteins only 192 
those from M. tb., S. enterica (figure 3B) and C. glutamicum (figure S2B) were able to 193 
terminate an elongating E.coli RNAP (see figure S2A for the inability of the other Rho 194 
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proteins).   In the presence of WT Psu, significant fractions of transcripts were found to read-195 
through the terminator regions (figure 3B, lanes 3, 5, 7 and the bar diagrams) when the M. tb 196 
and the S. enterica Rho proteins were used, whereas the effects of Psu was moderate on the 197 
C. glutamicum Rho (figure S2B). These results indicate that Psu is capable of inhibiting the 198 
termination function of the Rho proteins from these pathogens. 199 
As majority of the Rho proteins were not able to terminate the elongating E.coli 200 
RNAP, we hypothesized that these Rho proteins might be able to release RNA from a stalled 201 
elongation complex (EC) as kinetic coupling between Rho and the RNAP is not required if 202 
the latter is stalled on the DNA template.  So, we designed a set-up where the EC is stalled on 203 
a template bound to magnetic beads, at a particular position inside the trpt’ terminator (an 204 
E.coli Rho-dependent terminator) region using lac repressor as a roadblock (figure 3C). In 205 
this set-up, the terminated RNA would be released in the supernatant. After stalling the EC, 206 
all the NTPs were removed by washing the beads, following which Rho plus ATP either in 207 
the absence or presence of Psu   were added, and the RNA release was observed in the 208 
supernatant (figure 3D).  In the absence of WT Psu, Rho proteins from all the organisms, 209 
except Pseudomonas (figure S2C) could release RNA very efficiently.  It should be noted 210 
that for most of the Rho proteins from pathogens took longer time to release RNA from a 211 
divergent EC made of the E. coli RNAP (figures 3D and E).  In the presence of WT Psu, the 212 
RNA release by all the Rho proteins used in this study was significantly reduced from the 213 
stalled EC (figures 3D and E). RNA polymerase release assays (equivalent to RNA release 214 
assays), with the mutant Psu, CTD10, showed that it was unable to inhibit the dislodging of 215 
the polymerases as compared to its WT counterpart from the stalled ECs by the various Rho 216 
proteins (figure S3A). These observations strongly indicate that WT Psu is capable of 217 
specifically inhibiting the Rho proteins from several pathogenic species that is comparable to 218 
that observed for the E. coli Rho inhibition by this bacteriophage protein.  It should also be 219 
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noted that the Psu-induced inhibition of the RNA release efficiencies by different Rho 220 
proteins are qualitatively correlated with that observed for their respective ATPase assays.  221 
As the Rho-dependent termination function is a fundamental biological process of the 222 
prokaryotic world, we postulate that Psu would be able to inhibit these Rho proteins in the 223 
presence of their respective transcription system.  As Pseudomonas Rho was not able to 224 
release RNA from this stalled EC, we refrain to conclude that Psu would be an efficient 225 
inhibitor of Rho of this bacterium. 226 
Specific interaction of Psu with Rho proteins from different pathogens. 227 
Earlier a specific Psu- E. coli Rho complex formation was only demonstrated in vivo 228 
by co-overexpressing both the proteins in the same strain (11, 13, 14). We failed to get a 229 
stable in vitro complex with the purified components.  This is most likely due to the mis-230 
folding propensity of the unusually knotted dimer conformation of Psu (12).  Following the 231 
same procedure as before (11), we co-overexpressed a His-tagged Psu and a non-His tagged 232 
WT Rho from two different pET vectors and pulled down the complex using the Ni-NTA 233 
beads. Typically, after induction, the cell lysate was directly loaded onto Ni-NTA columns. 234 
The eluted fractions of WT Psu contained significant amounts of Rho proteins of E. coli, S. 235 
enterica and V. cholerae (figure 4B). For the X. campestris and X. oryzae Rho, both Rho and 236 
Psu were overexpressed in separate strains, and then the two lysates were mixed and loaded 237 
onto the Ni-NTA column. In all these cases, ~30% of Rho proteins were found to be 238 
associated with Psu that is comparable with what we observed for the E.coli Rho. P.syringae 239 
Rho was unable to bind to Psu even under in vivo conditions, which again indicated that Psu 240 
might not be an efficient antagonist of this Rho protein (figure S3B).  These interactions were 241 
specific as they were 4 to 7-fold weaker when a Psu mutant, CTD10 Psu, defective in 242 
inhibiting the Rho protein (11), was used in the various experiments (figure 4B). The 243 
expression levels of M. tuberculosis and C. glutamicum Rho proteins were very poor to 244 
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measure the complex formation by this procedure. These results suggest in vivo complex 245 
formation of Psu with some of the Rho proteins, at least in the cytoplasm of the E.coli, and 246 
we concluded that this interaction plays important role in inhibiting the Rho function. 247 
Psu-induced cell mortality upon expression in the pathogens. 248 
So far, we have established that the bacteriophage P4 coat protein, Psu, is capable of 249 
inhibiting in vitro functions of Rho proteins from a diverse set of bacteria most likely via a 250 
direct interaction with the latter.  In order to design a potent inhibitor of Rho from Psu, it is 251 
imperative that the latter’s expression in different bacterial strains should cause lethality or 252 
toxicity. We chose two of the Mycobacterium (gram positive) and one of the Xanthomonas 253 
(gram-negative) strain to study the in vivo effects of Psu, based on their availability and ease 254 
of handling. As the Salmonella Rho complements the deficiency of the E.coli Rho in vivo, we 255 
used an E.coli strain expressing Salmonella Rho to monitor the in vivo effects of the Psu.  As 256 
the Rho proteins of M. tb and M. bovis have the same sequence and also due to the relative 257 
ease of handling of the M. bovis strains compared to that of the M. tb. ones, we monitored the 258 
in vivo effect of Psu in a M. bovis strain.  259 
The Rho proteins of Salmonella enterica and E. coli are 99% homologous and thus 260 
the former can complement E. coli Rho in vivo. We deleted the chromosomal copy of rho of 261 
an E. coli MG1655 strain and supplied the S.enterica Rho from a plasmid pHYD3011 262 
(pRS1801). Subsequently, the strain was transformed with an IPTG- inducible plasmid 263 
having WT psu cloned under a Ptac promoter (figure 5A).  When this strain was streaked on 264 
plates containing the increasing concentrations of IPTG, causing the expression of Psu,  265 
severe growth inhibition was observed (figure 5A) that is similar to what was observed for 266 
E.coli Rho earlier (11, 14). This indicated that Psu inhibits S. enterica Rho efficiently in vivo. 267 
Xanthomonas campestris is a Gram-negative plant pathogen (infecting cabbage, 268 
mustard etc.) that produces a diffusible signal factor (DSF) responsible for the cell-cell 269 
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communication and different pathogenic aspects of the bacteria. We cloned the WT and the 270 
CTD20 psu (having a 20 amino acids deletion in its C-terminal; 11) under the control of a 271 
DSF-inducible promoter (Peng, pRS1574 and pRS1845, respectively) so that the naturally 272 
produced DSF will induce the expression of the Psu inside the X. campestris (figure 5B). We 273 
have used the strains, Xcc8004 (DSF producing) and Xcc8523 (rpfF mutant; DSF deficient) 274 
and transformed them with either pRS1574 (WT psu) or with pRS1845 (CTD20 psu) or 275 
with pRS1508 (empty vector). WT Xcc8004 did not produce any transformants when 276 
transformed with pRS1574, whereas Xcc8523 produced healthy colonies under the same 277 
conditions. Healthy colonies were also formed by both the strains when they were 278 
transformed with the empty vector pRS1508 or with the Psu mutant expressing pRS1845 279 
(figure 5B).  These observations indicated that rho is essential in X. campestris and its 280 
specific inhibition by Psu leads to cell mortality. 281 
We used M. smegmatis strain mc
2
155 and M. bovis BCG to monitor the effect of in 282 
vivo expression of Psu . We electroporated M. smegmatis with the pSTKT plasmids having 283 
WT psu (pRS1724), ΔCTD20 psu (pRS1837; 20 amino acid deletion at the C-terminal) and 284 
an empty vector (pRS1511).  In this vector, the psu genes are cloned under anhydrous 285 
tetracyclin (ATc) inducible Ptet promoter. The WT psu transformants were very small and 286 
few in number, and upon re-streaking they exhibited very poor growth (figure 5C), whereas 287 
the transformants expressing ΔCTD20 psu or having only the vector, upon re-streaking, grew 288 
well (figure 5C). We also performed similar experiments using the M. bovis BCG strain. 289 
There were very few transformants with heterogeneous sizes when the strain was transformed 290 
with pRS1724, whereas high number of transformants were observed when it was 291 
transformed with either pRS1837 or pRS1511 (figure 5D). Upon re-streaking these 292 
transformants, the WT psu expressing colonies showed very poor growth compared to those 293 
expressing the mutant psu.  Interestingly, in all the cases described (figures 5C and D), the 294 
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WT Psu inhibited growth even in the absence of the inducer, ATc.  Basal level expression of 295 
Psu was sufficient to cause severe growth defects in both of these Mycobacterium strains.  296 
Therefore, we concluded that Psu functions as a strong inhibitor of the Mycobacterium Rho 297 
in vivo.  298 
 299 
Discussion 300 
 The bacteriophage P4 capsid coat protein moonlights as a strong inhibitor of the 301 
E.coli transcription terminator, Rho (11). Rho is highly conserved protein among the 302 
prokaryotes (figure 1), and hence we hypothesized that Psu may function as a “universal” 303 
inhibitor of this transcription terminator from different bacteria. Here we tested the inhibitory 304 
properties  of the Psu protein against a diverse set of the Rho proteins (figure 1) and showed 305 
unequivocally that Psu  efficiently antagonizes the two most important functions of Rho, 306 
namely the ATPase activity and the transcription termination function (figure 3), which 307 
indicates a direct complex formation between the Psu and Rho proteins from different 308 
species.  We demonstrated this complex formation in vivo with the Rho proteins from four 309 
representative bacteria (figure 4).  Most importantly, we showed that in vivo expression of the 310 
Psu protein induces mortality of four pathogenic bacteria by antagonizing their transcription 311 
termination function (figure 5).  We concluded from the aforementioned results that this 312 
E,coli bacteriophage protein is capable of functioning as an universal antagonist of 313 
transcription termination of a wide range of bacteria (both gram positive and gram negative). 314 
We hypothesize that this phage protein could be useful for designing peptide-inhibitor(s) of 315 
the Rho. 316 
 It is interesting to note that Psu functions across genus boundaries when P4 is such a 317 
narrow host range phage. . Most of the bacteriophage derived protein factors target conserved 318 
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host machineries, like RNA polymerases etc.  The recently solved structures of the E.coli 319 
transcription modulators from the lambdoid phages, N (19) and Nun (20) in complex with the 320 
transcription elongation complex revealed that these factors target conserved regions around 321 
the active center of the RNAP. Hence, it could be predicted that these transcription regulators 322 
would also function with RNA polymerases from other bacteria.  Similarly, even though Psu 323 
is a unique protein of E.coli phage P4, it targets the universal ATPase domain present in this 324 
conserved transcription termination factor Rho of different bacteria.  Therefore, the host 325 
range of the phages and the nature of the cellular targets may not necessary be correlated. 326 
 The Rho protein could be a potent drug target for following several reasons. I) It is 327 
structurally and functionally highly conserved in most of the bacteria (1), which makes drug 328 
designing possible for the Rho proteins from different pathogens based on the structure of the 329 
E.coli Rho (15). II) The Rho-dependent termination is involved in many important 330 
physiological processes [9], affecting any of them could cause lethality of the bacteria. III) It 331 
has been recently shown that the Rho-dependent termination is involved in the pathogenicity 332 
of the Mycobacterium tuberculosis (21).  Bicyclomycin is the only known antibiotic that 333 
binds to Rho (22-24), but its application is limited due to its inability to cross the cell 334 
membrane of the gram positive pathogens and due to its high cytotoxicity (25, 26).  In this 335 
backdrop, the present study establishing the potential of Psu to inhibit Rho proteins from 336 
wide varieties of pathogens could enable us to design new Rho inhibitor(s). Compromising 337 
the Rho function might also be used as a component of co-synergistic treatment regime 338 
together with other antibiotics, which would have great implications in the treatment of 339 
Multi-drug resistant (MDR) and Extensively-drug resistant (XDR) bacterial strains. 340 
  We have shown earlier that the helical C-terminal 20 amino acids region of Psu 341 
makes direct contacts with Rho (12, 13).  It is revealed from biochemical probing and its 342 
crystal structure (13) that the helices 6 and 7 forming the C-terminal Rho binding region are 343 
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surface exposed and forms the tip of the arms of the V-shaped knotted dimer of Psu. It 344 
appears from the structure that the rest of the Psu dimer functions as a scaffold to hold these 345 
helices nearer to the Psu-binding loop region (see figure 1) of the Rho so that the local 346 
concentrations of the helices increases due to the reduction of the entropy of the C-terminal 347 
domain of the former.  We speculate that the sequences of these helices could function as a 348 
template to design peptide inhibitors of the Rho protein. Ideally, these peptide sequences 349 
must have higher affinities for the Rho protein so that they can bind in the absence of rest of 350 
the Psu-scaffold. It would be interesting to know whether these two helices or their sequence 351 
variations in isolation could interact with Rho and elicit the antagonizing function. 352 
The bacteriophages are the large reservoirs of unique proteins that are capable of 353 
modulating many bacterial machineries for their own advantage. Like the Psu, most of these 354 
protein modulators do not have any homology with the known proteins from all the three 355 
kingdoms. The modulation of the host machineries by them are usually executed through 356 
direct interactions with the key host proteins and regulatory DNA and RNA sequences, 357 
leading to complete shutdown of the host metabolism and the eventual killing.  In addition to 358 
the effectiveness of these phage modulators, they are small in size, which makes them more 359 
amicable to function as a platform for designing new peptide inhibitors. A crude estimate 360 
measures the number of bacteriophage particles to be 10
31 
(27).  Therefore, theoretically, this 361 
reservoir is capable of producing “infinite” numbers of these modulators specific for each of 362 
the pathogenic bacteria, and the number surpasses the capacity of the chemical libraries that 363 
are presently in use. We envision that the bacteriophage-modulator libraries, products of 364 
natural origin, could become a cheaper alternative to the chemical libraries. 365 
 366 
Materials and Methods. 367 
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Materials.  NTPs were purchased from GE Healthcare. [γ-32P]ATP (3000 Ci/mmol) and [α-368 
32
P]CTP (3000 Ci/mmol) were obtained from Jonaki, BRIT (Hyderabad, India). Antibiotics, 369 
IPTG, lysozyme, DTT and BSA were from U.S. Biochemical Corp. Restriction 370 
endonucleases, polynucleotide kinase, and T4 DNA ligase were from New England Biolabs. 371 
WT E. coli RNA polymerase holoenzyme was purchased from Epicenter Biotechnologies and 372 
New England Biolabs. Streptavidin coated magnetic beads were from Promega. Taq DNA 373 
polymerase was obtained from Roche Applied Science. Ni-NTA-agarose beads were from 374 
Qiagen.  375 
Details of the bacterial strains and plasmids are described in Table 1. 376 
Cloning, expression and purification of recombinant Rho proteins of different bacterial 377 
species: Genomic DNA was isolated from the pathogens Salmonella enterica, 378 
Corynebacterium glutamicum, Xanthomonas oryzae, Xanthomonas campestris and 379 
Pseudomonas syringae using the genomic DNA isolation kit (Invitrogen). The rho genes 380 
were PCR-amplified from the genomic DNA using Deep Vent DNA polymerase (NEB) and 381 
were cloned in NdeI-XhoI sites of the pET28b vector. All the clones were sequenced.  E. coli 382 
and M. tuberculosis Rho were available from the lab-stock (11, 17). Vibrio cholerae Rho 383 
cloned in pET28a was a gift from Prof U. Sen (SINP, Kolkata). The Rho proteins were 384 
overexpressed in BL21 (DE3) cells and purified using Ni-NTA beads (Qiagen) as per the 385 
manufacturer’s protocol. The proteins eluted from the Ni-NTA columns were further purified 386 
by passing through a HiTrap Heparin HP sepharose column (GE healthcare). 387 
ATPase activities of Rho: The rates of RNA-dependent ATP hydrolysis of Rho proteins of 388 
different bacterial species were measured using poly (rC) as template.  ATP hydrolysis was 389 
assayed by monitoring the release of Pi from ATP that was observed on the polyethylenimine 390 
TLC plates using 0.75 M KH2PO4 (pH 3.5) as a mobile phase buffer. The hydrolysis 391 
reactions were performed in T buffer (25mM Tris-HCl (pH 8.0), 50mM KCl, 5mM MgCl2, 1 392 
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mM DTT, and 0.1 mg/ml BSA) at 37°C. The rate of ATP hydrolysis of 1mM ATP mixed 393 
with [γ-32P] ATP (3500 Ci/mmol; BRIT, India) were measured using 50 nM of each Rho 394 
from different bacterial species. The reactions were initiated by the addition of 20μM RNA. 395 
Aliquots were removed, and the reactions were stopped with 1.5 M formic acid at various 396 
time points. Release of Pi was analysed by exposing the TLC sheets to a Phosphor-Imager 397 
screen and subsequently by scanning using FLA 9000 (Typhoon). 398 
Psu-mediated inhibition of the Rho ATPase activities were measured using λtR1 RNA 399 
as template for E. coli Rho.  This RNA has one of the strongest rut sites for E. coli Rho 400 
protein.  Poly (rC) was used for all other Rho proteins except Salmonella Rho. Oligo rC25 was 401 
used in case of S.enterica Rho. Reactions were initiated with the Rho proteins in the presence 402 
or absence of the WT and CTD10 Psu proteins and were stopped at a final time point where 403 
maximum hydrolysis occurred.  Other reaction conditions were same as described above. 404 
Templates for in vitro transcription assays: Linear DNA templates for in vitro transcription 405 
and RNA release assays were made by PCR amplification from the plasmids, pRS604 (PT7A1-406 
λtR1) and pRS106 (PT7A1-trpt’) using the oligo pairs RS58/RS147 and RS83/RS177, 407 
respectively. To form a road-block (RB) on the template, a 22-bp lac operator sequence was 408 
inserted after the trpt’ terminator sequence using a downstream primer (RS177) having the 409 
lac operator sequence (28). A transcription elongation road-block is formed at this sequence 410 
in the presence of lac repressor. To immobilize the DNA templates to the streptavidin-coated 411 
magnetic beads (Promega), a biotin group at the 5’-end of the templates was incorporated by 412 
using a biotinylated primer (RS83). 413 
In vitro transcription assays: In vitro transcription assays were performed on PT7A1-λtR1 414 
template, where transcription was initiated from the strong T7A1 promoter and elongation 415 
occurs through the Rho-dependent terminator, λtR1.  Transcription reactions were performed 416 
in the presence of rifampicin in the transcription buffer (T-buffer; 25mM Tris-HCl (pH 8.0), 417 
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5mM MgCl2, 50mM KCl, 1mM DTT, and 0.1mg/ml BSA). At first, a 23-mer elongation 418 
complex, EC23, was formed by mixing 5nM DNA template, 25nM RNA polymerase, 175μM 419 
adenylyl (3’-5’)-uridine, 5μM each of the ATP and GTP and 2.5μM CTP. [α-32P]CTP 420 
(3000Ci/mmol, BRIT, Hyderabad) was used for labeling the transcripts. This EC was then 421 
chased with 20μM NTPs for 15 min. Samples were run onto 8% sequencing gel and analyzed 422 
by FLA-9000 PhosphorImager (Typhoon). 423 
RNA release assays from RB complex. For the RNA release assays from the stalled ECs (RB), 424 
the PT7A1-trpt’-lacO template immobilized on streptavidin-coated magnetic beads was used. 425 
100 nM lac repressor was added to the DNA templates to form a RB.  On this template, at 426 
first the EC23 was formed by initiating the reactions with 175μM adenylyl (3’-5’)-uridine, 427 
5mM GTP, 5mM ATP, 2.5mM CTP, and [α-32P]CTP (3000 Ci/mmol). This complex was 428 
then chased with 250 μM each of the NTPs. Following the chase, excess NTPs were removed 429 
by washing the beads thoroughly. 50 nM Rho and 5 μM Psu (when required) were added to 430 
the RB and 10μl of samples were removed at the indicated time points for each Rho (that 431 
varied for different Rho proteins), separated into S (half of the supernatant) and P (other half 432 
of supernatant + pellet) on the magnetic stand. The rest of the procedures were same as 433 
described above. The fractions of released RNA [2S/{S + (S+P)}] were measured for each of 434 
the Rho proteins. 435 
RNA polymerase release assays from the RB complex. RNA polymerase release from the 436 
stalled ECs (RB) on PT7A1-trpt’-lacO template immobilized on the streptavidin-coated 437 
magnetic beads was carried out following the similar procedures as above. The radioactive 438 
CTP was not included in these experiments. 50 nM of each types of the Rho, 5 μM WT or 439 
ΔCTD10 Psu proteins were added to the RB and 10μl of samples were removed at the 440 
indicated time points.  Supernatant (S) and the pellet (P) fractions were separated by keeping 441 
the samples against a magnetic stand; S fraction was removed directly, whereas the P 442 
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fractions were re-suspended in equal volume of the T buffer. These two fractions were then 443 
loaded onto a SDS PAGE, and analysed by western blotting. The RNA polymerase release 444 
was detected using an anti-RpoC monoclonal antibody (Neoclone). 445 
In vivo pull down assays: BL21 (DE3) strain was co-transformed with the plasmids pET28 446 
(kan
r
) expressing WT or CTD Psu proteins, and pET21 (ampr), expressing Rho proteins 447 
from E. coli, S. enterica and V.cholerae.  Psu proteins were His-tagged at the N-terminus. 448 
The Transformants were inoculated in 5 ml of LB and were grown at 37°C for ~3 h. The 5ml 449 
culture was then added to 100 ml of LB and grown until OD600 ~0.3, following which 0.1mM 450 
IPTG was added to induce the protein expressions and the induction was continued for 3 h. 451 
The cells were then lysed in the lysis buffer (100mM NaH2PO4, 100mM NaCl, 10mM 452 
imidazole, 1 mg/ml of lysozyme and 10 mg/ml of PMSF). The lysate was passed through Ni-453 
NTA (Qiagen) affinity columns, washed with wash buffer (100mM NaH2PO4, 100mM NaCl 454 
and 20mM imidazole), and the proteins were eluted with the elution buffer (100mM 455 
NaH2PO4, 100mM NaCl and 500mM imidazole). The volumes of lysate, wash buffer and 456 
elution buffers were kept same for loading of the same amount of proteins in each lane. Rho 457 
proteins of X. oryzae, X. campetsris, M. tuberculosis and C. glutamicum could not be co-458 
overexpressed with Psu. Thus, the Rho proteins of Xanthomonas species and both types of 459 
the Psu proteins were overexpressed separately and then the lysates of the two were mixed 460 
and pull-down was carried out in the same way as described above.  The mixing was done for 461 
at least 2hrs. Expression levels of Rho proteins of M. tb and C. glutamicum were very low, so 462 
the mixing experiments were not attempted. 463 
In vivo growth inhibition assays. 1)  S. enterica Rho inhibition in E. coli:  S. enterica rho was 464 
cloned in pHYD3011 under the control of PBAD promoter. pHYD3011carrying S. enterica rho 465 
was transformed into the E. coli MG1655 WT strain. The chromosomal rho was subsequently 466 
deleted from the MG1655 strain. S. enterica rho complemented E. coli rho after the deletion 467 
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of the chromosomal rho. These strains were transformed then with pNL150 expressing psu 468 
cloned under an IPTG-inducible promoter, Ptac, and the transformants were streaked on the 469 
plates containing different IPTG concentrations. 470 
II) M. smegmatis mc
2
155 and M. bovis:  WT psu, and Δ20CTD psu (20 amino acid deletions at 471 
the C-terminal ) were PCR-amplified from the pNL150-psu plasmid by  Deep Vent DNA 472 
polymerase (NEB), and were cloned in the EcoRI / HindIII sites of pSTKT plasmid, a 473 
Mycobacterial / E.coli shuttle vector having a PtetO (ATc, anhydrous tetracycline  inducible).  474 
Next we electroporated WT andΔ20CTD psu and the empty vector into the M. smegmatis 475 
mc
2
155 strain following the published protocol (29). Transformants were grown at 37°C for 4 476 
days in the Diffco Middlebrook 7H10 agar plates supplemented with 10% OADC (oleic 477 
albumin dextrose catalase) and 0.2% glycerol in the presence of 10g/ml Kanamycin and 478 
were further purified in higher concentration (25μg/ml) of Kanamycin containing media. 479 
Subsequently, colonies were patched on the plates to study the effect of psu expression on the 480 
cell viability of M. smegmatis.  In the same way, the M. bovis strain was transformed with 481 
plasmids having different psu derivatives following the procedures described above.  The 482 
transformants were grown for 3 weeks under same conditions as used for M. smegmatis. The 483 
transformants expressing WT or mutant Psu proteins were re-streaked subsequently. 484 
III)  X. campestris and X. oryzae: WT and CTD20 psu were cloned in SalI/HindIII sites of 485 
pKLN55, a Xanthomonas shuttle vector having a Peng promoter (DSF, diffusible signal 486 
factor-inducible endoglucanase gene promoter). X. campestris strains Xcc 8004 WT (DSF 487 
producing) and Xcc 8523 (rpfF mutant; DSF non-producing) were electroporated with the 488 
pKLN55 plasmids with and without the WT or mutant psu. The transformants were grown in 489 
Peptone Sucrose agar media at 28°C.  490 
Multiple sequence alignment and homology modelling of Rho protein of different species: All 491 
sequences of Rho proteins from selected bacterial species were submitted to Clustal Omega 492 
 o
n
 M
ay 28, 2018 by guest
http://jb.asm.org/
D
ow
nloaded from
 
22 
 
online server (30) to obtain the multiple sequence alignment. The phylogenetic tree was built 493 
from the multiple sequence alignment of 16S RNA by using SeaView software (31) and by 494 
the distance BioNJ (32). Homology modelling of all the Rho proteins were performed by 495 
MODELLER version 9v17 (33) software. The E. coli Rho crystal structure (PDB code: 496 
3ICE) was used as template for the modelling. The best model was selected on the basis of 497 
DOPE (Discrete optimized protein energy), a statistical method optimized for model 498 
assessment. All Rho monomers from different species were superimposed in the UCSF 499 
Chimera Version1.11 software (34) and the Psu-binding regions were highlighted in each of 500 
the Rho monomers. 501 
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Figure 1. Sequential and structural homology among the Rho proteins from different 612 
pathogenic bacteria. (A) A phylogenetic tree, constructed based on the 16S rRNA sequences, 613 
demonstrating the diversity of the different pathogenic bacteria from which the Rho proteins 614 
were selected in this study. (B) The sequence alignment of the region enclosing the Psu-615 
binding sites from different Rho proteins produced by Clustal Omega software. The locations 616 
of the residues responsible for the Psu binding are indicated. (C) Homology models of Rho 617 
hexamers obtained by Modeller, using the crystal structure of the E. coli Rho as a template 618 
(PDB 3ICE) [15]. Red loops on each structure indicates the unstructured Psu-binding region. 619 
(D) Superimposed monomer structures of all the Rho proteins highlighting the Psu-binding 620 
loops. A zoomed in view of the loops have been shown. 621 
 Figure 2. Purification and characterization of the Rho protein activities from different 622 
pathogenic bacteria. (A) SDS PAGE showing the migration patterns of the recombinant Rho 623 
proteins of different species. (B-D) The ATPase activities of these Rho proteins in the 624 
presence of poly(rC) as substrate. The Rho proteins having similar rates of ATPase activities 625 
are shown together in each of the panels as indicated. The activity of E.coli Rho has been 626 
included all the panels for comparison. D) Table showing the values of the ATPase activities 627 
of all the Rho proteins expressed in nmol/min/g. 628 
Figure 3. ATPase and in vitro transcription assays showing Psu mediated inhibition of the 629 
activities of Rho from different pathogens. (A) Bar diagrams showing the fractions of ATP 630 
hydrolyses by each of the Rho protein in the absence and presence of 1 M and M Psu. In 631 
control experiments, 5 M of a Psu mutant, CTD10, was used. Similar to figure 2, poly (rC) 632 
was used as substrate for all the Rho proteins except for those from E.coli and Salmonella.  633 
For E.coli, a RNA with λtR1 terminator was used, whereas rC25 oligo RNA was used for 634 
Salmonella Rho protein. Errors were calculated from 3 independent measurements. (B) Left 635 
panel, autoradiograms showing the in vitro Rho-dependent transcription termination assays 636 
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using Rho proteins of E.coli, S. enterica and M. tuberculosis performed on a DNA template 637 
having the  λtR1 terminator (see the adjacent cartoon), both in the absence and presence of 5 638 
M Psu in the reaction mixture. Termination zone is indicated. Right panel, bar diagrams 639 
showing the fractions of Run-off (RO) product under different conditions.  This is calculated 640 
using the formulae: (Intensity of the Run-off product)/ (Intensities of all the terminated 641 
products + Intensity of the Run-off product).  Errors were calculated from 3 independent 642 
measurements.  (C) Cartoon showing the stalled elongation complex (EC) at a lac repressor 643 
road-block located downstream of the trpt’ terminator.  On this template, transcription is 644 
initiated from the T7A1 promoter and the RNA release was induced from the stalled EC by 645 
different Rho proteins as indicated in D.  Template is immobilized via an attachment to a 646 
magnetic bead to monitor the released RNA.  D) Autoradiogram showing the RNA release in 647 
the supernatant fractions (S: half of the Supernatant).  Rest of the fractions were in the pellet 648 
fraction (P: other half of the supernatant and whole of the pellet).  RNA products in different 649 
fractions are shown in the presence and absence of Psu.  Time of incubation of the stalled 650 
ECs with different Rho proteins are indicated. RB denotes the RNA product of the stalled 651 
EC. (E) Amount of RNA released under different conditions in figure (D) are expressed as 652 
bar diagrams.  Fractions of released RNA was calculated as: (2S)/[(S) + (S+P)]. Errors were 653 
measured from 3 independent experiments. 654 
Figure 4. Complex formation of Psu with different Rho proteins.  In vivo pull-down assays 655 
showing direct complex formation between different Rho and A) WT Psu and B) CTD10 656 
Psu proteins. Flow through (FT) and wash (W) fractions contain the unbound Rho, whereas 657 
the amounts of protein in elute (E) fraction gave the measure of the Psu-bound Rho. Both the 658 
proteins bands are indicated. Fractions of Rho associated was calculated as: [E] / 659 
{[FT]+[W]+[E]}. Values are shown below the gel pictures.  Errors were calculated from two 660 
to three independent measurements. 661 
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Figure 5. Psu induced lethality of different bacteria. (A) MG1655 Δrho::kan strains 662 
expressing Salmonella enterica Rho from the pHYD3011 plasmid were transformed together 663 
with the second plasmid expressing WT Psu. Strains were streaked on LB plates in the 664 
presence and absence of different concentrations of the inducer IPTG as indicated. (B) 665 
Xanthomonas campestris strain Xcc8004 WT producing the inducer, DSF and Xcc8523, a 666 
DSF deficient strain (rpfF mutant), were transformed with pRS1574 (a Xanthmonas shuttle 667 
vector, pKLN55) (expressing. WT Psu) and pRS1508 (empty pKLN55 vector). The Xcc8004 668 
strain was also transformed with pRS1845 expressing CTD20 Psu.. Plates with the 669 
transformants are shown. Cartoon above the plates showing the location of psu under the 670 
control of Peng. The transformants obtained upon transforming the strain Xcc8004 with 671 
pRS1508 and pRS1845 were streaked separately to show the inability of the Psu mutant to 672 
cause mortality. (C) Mycobacterium smegmatis strain mc
2
155 was  transformed with either  673 
pSTKT empty vector (pRS1511) or  expressing either WT Psu (pRS1724) or the mutant Psu, 674 
CTD20  (pRS1837). Transformants were subsequently patched on the 7H10 plates.  675 
Location of the WT or mutant psu under the ATc (anhydrous tetracycline) inducible promoter 676 
Ptet is shown as a cartoon. (D)  The Mycobacterium bovis BCG strain, was  transformed with 677 
the same plasmids described in (C).  Transformants obtained after 3 weeks are shown, and in 678 
two of the cases, colonies were further streaked to show the growth differences of the M. 679 
bovis strains upon expression of either WT or mutant Psu proteins.   680 
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Table 1: Strains and plasmids used in the study 681 
Strains Genotype Reference 
RS 1263                           E. coli MG1655 K12 WT Lab stock 
RS 1487                             M. smegmatis mc2155 WT From Dr Sangita 
Mukhopadhyay  
RS 1833                             X. campestris Xcc8004 WT From Dr Subhadeep 
Chatterjee 
RS 1835                             X. campestris Xcc8523 DSF-deficient rpfF mutant From Dr Subhadeep 
Chatterjee 
RS 1838                            M. bovis BCG WT From Dr Sanjeev Khosla 
Plasmids   
pRS 96 pET21b with E. coli rho cloned at NdeI/XhoI site, His tag at C-
terminal, AmpR 
[18] 
pRS 100 pET21b with E. coli rho cloned at NdeI/XhoI site, Non-His tagged, 
AmpR 
[11] 
pRS 106 pT7A1 clone at EcoRI/HindIII sites upstream of trpt’ cloned at 
HindIII/BamHI sites of pK8641, AmpR 
[11] 
pRS 258 pNL150 with Ptac-WT psu, CamR                                                                                                                         [33] 
pRS 458 pET 28b with WT Psu cloned at NdeI/XhoI site, His tag at N-terminal, 
KanR 
[11] 
pRS 460 pET 28b with Δ20CTD psu cloned at NdeI/XhoI site, His tag at N-
terminal, KanR 
[11] 
pRS 553 pET28a with M. tb rho cloned at NdeI/XhoI site, His tag at N-terminal, 
AmpR 
[17] 
pRS 604  pTL61T with pT7A1-Lambda nutR-tR1-T1T2-lacZYA; AmpR [14]  
pRS 1508 pKLN55 Xanthomonas shuttle vector with Peng, Spec
R                                                                                [36] 
pRS 1511 pSTKT mycobacterial shuttle vector with PtetO, Kan
R                                                                                      [37] 
pRS 1574 pKLN55 with WT psu cloned at SalI/HindIII site, SpecR                                                                                       This study 
pRS 1670          pET28b with P. syringae rho cloned at NdeI/XhoI site, His tag at N-
terminal, KanR                                      
This study 
pRS 1671 pET28b with X. oryzae rho cloned at NdeI/XhoI site, His tag at N-
terminal, KanR 
This study 
pRS 1672 pET28b with X. campestris rho cloned at NdeI/XhoI site, His tag at N-
terminal, KanR               
This study 
pRS 1680 pET28b with S. enterica rho cloned at NdeI/XhoI site, His tag at N-
terminal, KanR                                
This study 
pRS 1681 pET28b with C. glutamicum rho cloned at NdeI/XhoI site, His tag at 
N-terminal, KanR                       
This study 
pRS 1724 pSTKT with WT psu cloned at EcoRI/HindIII site, KanR                                                                                     This study 
pRS 1770 pET28a with V. cholerae rho cloned at NdeI/BamHI site, His tag at N-
terminal, KanR                          
From Dr U. Sen 
pRS 1779 pET21b with X. oryzae rho cloned at NdeI/XhoI site, Non-His tagged, 
AmpR                                                                                   
This study 
pRS 1780 pET21b with S. enterica rho cloned at NdeI/XhoI site, Non-His 
tagged, AmpR                                                                                 
This study 
pRS 1781 pET21b with V. cholerae rho cloned at NdeI/XhoI site, Non-His 
tagged, AmpR                                                                                 
This study 
pRS 1785 pET21b with X. campestris rho cloned at NdeI/XhoI site, Non-His 
tagged, AmpR                                                                           
This study 
pRS 1801 pHYD3011 with S. enterica rho cloned at NdeI/SalI site, Non-His This study 
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tagged, AmpR                                                                               
pRS 1837 pSTKT with ΔCTD20 psu cloned at EcoRI/HindIII site, Kan
R                                                                                
 This study 
pRS1845 pKLN55 with ΔCTD20 psu cloned at SalI/HindIII site, Spec
R                                                                                 This study 
Oligos   
RS58 ATAAACTGCCAGGAATTGGGGATC; located upstream of T7A1 
promoter of pRS106 
[26] 
RS83 ATAAACTGCCAGGAATTGGGGATC;5’-biotinylated RS58 [26] 
RS147 GCGCGCGGATCCCCCCATTCAAGAACAGCAAGCAGC, reverse 
oligo to generate T7A1-λtR1 terminator template 
[26] 
RS177 TTGTGAGCGCTCACAATTCGGATATATATTAACAATTACCTG; 
reverse oligo with lac operator sequence, used to generate roadblock 
downstream of rut sites of T7A1-trp t’ template 
[26] 
 682 
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